AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16647411 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-D immune globulin at 75 microg/kg (anti-D75)
Number of subjects: 105
Study 16647411 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-D immune globulin at 50 microg/kg (anti-D50)
Number of subjects: 105
Study 16647411 — intervention group
Group type: EXPERIMENTAL
Intervention: intravenous immune globulin (IVIg) at 0.8 g/kg
Number of subjects: 105
Study 12540113 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% carbamide peroxide (Opalescence Quick)
Number of subjects: 27
Study 12540113 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (Opalescence Xtra)
Number of subjects: 27
Study 12540113 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water at 37 degrees C)
Number of subjects: 27
Study 10966281 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 12
Study 10966281 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation (HV)
Number of subjects: 12
Study 10966281 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of iNO and HV
Number of subjects: 12
Study 8613834 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with aneurysmal subarachnoid hemorrhage
Number of subjects: 906
Study 8613834 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with aneurysmal subarachnoid hemorrhage
Number of subjects: 906
Study 8613834 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 906
Study 8613834 — intervention group
Group type: EXPERIMENTAL
Intervention: Women and men
Number of subjects: 906
Study 1505608 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 27
Study 1505608 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 27
Study 6407429 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg slow release isosorbide dinitrate (ISDN group)
Number of subjects: 30
Study 6407429 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg slow release nitroglycerin (NTG group)
Number of subjects: 30
Study 6407429 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 30
Study 31926465 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Number of subjects: 239
Study 31926465 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg
Number of subjects: 239
Study 30071855 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention using social media and face-to-face sessions (REDUCE programme)
Number of subjects: 134
Study 30071855 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 134
Study 27184785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen IR/ER
Number of subjects: 654
Study 24816453 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TCC)
Number of subjects: 32
Study 24816453 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk Walking (BW)
Number of subjects: 32
Study 24816453 — intervention group
Group type: COMPARATOR
Intervention: No Exercise Habit (NEH)
Number of subjects: 32
Study 22371525 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily electronic transmission of body weight to HF clinic using an electronic scale.
Number of subjects: 319
Study 20065886 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupoint stimulation
Number of subjects: 40
Study 20065886 — intervention group
Group type: COMPARATOR
Intervention: Placebo (laser off)
Number of subjects: 40
Study 18158500 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin
Number of subjects: 4731
Study 18158500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4731
Study 15699284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/d
Number of subjects: 5408
Study 15699284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5408
Study 15699284 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy with tamoxifen
Number of subjects: 5408
Study 12818947 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (100-200 micro g x kg(‐1) x min(‐1)) with 60% N(2)O in O(2)
Number of subjects: 60
Study 12818947 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (end-tidal concentration 0.8%) with 60% N(2)O in O(2)
Number of subjects: 60
Study 11905407 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative selective gut decontamination (SGD) with oral nonabsorbable antibiotics (polymyxin B and neomycin) for 5 to 7 days
Number of subjects: 78
Study 11905407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 11905407 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative selective gut decontamination (SGD)
Number of subjects: 78
Study 10468001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine whey protein fortifier
Number of subjects: 32
Study 10468001 — intervention group
Group type: COMPARATOR
Intervention: Ultrafiltrated human milk protein
Number of subjects: 32
Study 8751020 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atropine (0.03 mg/kg)
Number of subjects: 7
Study 8751020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular atropine (0.02 mg/kg)
Number of subjects: 7
Study 2096742 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine 1/200,000 epinephrine
Number of subjects: 0
Study 2096742 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine 1/100,000 epinephrine
Number of subjects: 0
Study 2096742 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine 1/200,000 epinephrine
Number of subjects: 0
Study 7471712 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole virus vaccine
Number of subjects: 304
Study 7471712 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental vaccine (A-EV)
Number of subjects: 304
Study 7471712 — intervention group
Group type: EXPERIMENTAL
Intervention: Split vaccine
Number of subjects: 304
Study 7471712 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit vaccine
Number of subjects: 304
Study 31163515 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation writing exercises
Number of subjects: 562
Study 31163515 — intervention group
Group type: COMPARATOR
Intervention: Control condition (neutral topic writing)
Number of subjects: 562
Study 30865350 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D image analysis tool for facial pore characterization
Number of subjects: 55
Study 28630468 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training of P4 alpha activity for two days
Number of subjects: 0
Study 25776198 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary Reverse Mapping (ARM) procedure
Number of subjects: 265
Study 25776198 — intervention group
Group type: COMPARATOR
Intervention: Traditional axillary lymph node dissection (ALND)
Number of subjects: 265
Study 24074027 — intervention group
Group type: EXPERIMENTAL
Intervention: OCP (30 μg ethinyl E2/150 μg levonorgestrel) for 12-16 days
Number of subjects: 100
Study 24074027 — intervention group
Group type: COMPARATOR
Intervention: E2 valerate (4 mg/day) for 5-12 days
Number of subjects: 100
Study 21377073 — intervention group
Group type: COMPARATOR
Intervention: Heine Classic+ Macintosh metal blades (Group M)
Number of subjects: 519
Study 21377073 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital View plastic blades (Group V)
Number of subjects: 519
Study 21377073 — intervention group
Group type: EXPERIMENTAL
Intervention: Heine XP plastic blades (Group H)
Number of subjects: 519
Study 19696205 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy (MNT) program
Number of subjects: 174
Study 19696205 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital routine care (Control)
Number of subjects: 174
Study 17414703 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG) induction with steroids
Number of subjects: 0
Study 17414703 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG) induction without steroids
Number of subjects: 0
Study 17414703 — intervention group
Group type: COMPARATOR
Intervention: Antilymphocyte globulin (ALG) induction (both groups)
Number of subjects: 0
Study 15071483 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined massage and physical activity (Group II)
Number of subjects: 30
Study 15071483 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 30
Study 11528581 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent monitoring (at baseline and every 2 months)
Number of subjects: 206
Study 11528581 — intervention group
Group type: COMPARATOR
Intervention: Infrequent monitoring (at baseline and twice yearly)
Number of subjects: 206
Study 11528581 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent monitoring
Number of subjects: 206
Study 9146258 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative standardization of diagnosis and treatment of R/O sepsis patients
Number of subjects: 0
Study 9146258 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative approach between nurses and physicians
Number of subjects: 0
Study 8311073 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study 3371082 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g or 10% fructose-1,6-diphosphate (FDP) twice daily for 7 to 10 days
Number of subjects: 30
Study 3371082 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 30
Study 29661746 — intervention group
Group type: EXPERIMENTAL
Intervention: 200.000 IU vitamin D every 3 months
Number of subjects: 132
Study 29661746 — intervention group
Group type: COMPARATOR
Intervention: 30.000 IU vitamin D every month
Number of subjects: 132
Study 26952547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg) plus oral prednisolone
Number of subjects: 30
Study 26952547 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus oral prednisolone
Number of subjects: 30
Study 23656601 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (ET) - jaw movement exercise (JME)
Number of subjects: 39
Study 23656601 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (ET) - jaw movement exercise (JME) and psychological intervention (PI)
Number of subjects: 39
Study 23656601 — intervention group
Group type: COMPARATOR
Intervention: Control group - pharmacological treatment only
Number of subjects: 39
Study 22573363 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based bilateral renal denervation
Number of subjects: 0
Study 22573363 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20379853 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe (E group)
Number of subjects: 86
Study 20379853 — intervention group
Group type: EXPERIMENTAL
Intervention: orlistat (O group)
Number of subjects: 86
Study 20379853 — intervention group
Group type: EXPERIMENTAL
Intervention: both ezetimibe and orlistat (OE group)
Number of subjects: 86
Study 20379853 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study 18355411 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean pine nut FFA (3 g)
Number of subjects: 18
Study 18355411 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean pine nut TG (3 g)
Number of subjects: 18
Study 18355411 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 18
Study 15735101 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (26.6 +/- 4.5 g protein/d containing 44.4 +/- 7.5 mg isoflavones/d)
Number of subjects: 40
Study 15735101 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein + probiotics (10^9 colony-forming units Lactobacillus acidophilus DDS(R)+1 & Bifidobacterium longum, 15-30 mg fructooligosaccharide/d)
Number of subjects: 40
Study 15735101 — intervention group
Group type: COMPARATOR
Intervention: Milk protein (26.6 +/- 4.5 g protein/d)
Number of subjects: 40
Study 15735101 — intervention group
Group type: COMPARATOR
Intervention: Milk protein + probiotics
Number of subjects: 40
Study 15532128 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutionalized group
Number of subjects: 0
Study 15532128 — intervention group
Group type: COMPARATOR
Intervention: Never-institutionalized group
Number of subjects: 0
Study 10780953 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (EPI) at 0.1 microg x kg(‐1) x min(‐1) from 30 to 40 min
Number of subjects: 7
Study 10780953 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) without epinephrine infusion
Number of subjects: 7
Study 8831469 — intervention group
Group type: EXPERIMENTAL
Intervention: Persons with SCI
Number of subjects: 167
Study 8831469 — intervention group
Group type: COMPARATOR
Intervention: Age- and sex-matched control group from the general population
Number of subjects: 167
Study 8831469 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 167
Study 1310159 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptozocin plus doxorubicin
Number of subjects: 105
Study 1310159 — intervention group
Group type: COMPARATOR
Intervention: Streptozocin plus fluorouracil
Number of subjects: 105
Study 1310159 — intervention group
Group type: COMPARATOR
Intervention: Chlorozotocin alone
Number of subjects: 105
Study 1310159 — intervention group
Group type: COMPARATOR
Intervention: Crossover therapy after failure of chlorozotocin or combination regimens
Number of subjects: 105
Study 4077362 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (cyclo-oxygenase-inhibiting drug)
Number of subjects: 6
Study 4077362 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 6
Study 3688595 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-Char (57.76% reduction in aspirin absorption)
Number of subjects: 7
Study 3688595 — intervention group
Group type: EXPERIMENTAL
Intervention: Actidose-Aqua (50.42% reduction in aspirin absorption)
Number of subjects: 7
Study 3688595 — intervention group
Group type: EXPERIMENTAL
Intervention: Insta-Char (39.55% reduction in aspirin absorption)
Number of subjects: 7
Study 3688595 — intervention group
Group type: EXPERIMENTAL
Intervention: Liqui-Char (33.40% reduction in aspirin absorption)
Number of subjects: 7
Study 3688595 — intervention group
Group type: EXPERIMENTAL
Intervention: Acta-Char (27.46% reduction in aspirin absorption)
Number of subjects: 7
Study 3688595 — intervention group
Group type: COMPARATOR
Intervention: Control phase (baseline aspirin absorption with 2,592 mg aspirin)
Number of subjects: 7
Study 31408152 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) services
Number of subjects: 21
Study 31408152 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of first and second line antiretroviral (ARV) medication
Number of subjects: 21
Study 31408152 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical consultations
Number of subjects: 21
Study 31408152 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient compliance with drug use
Number of subjects: 21
Study 31408152 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' knowledge of HIV/AIDS transmission prevention
Number of subjects: 21
Study 31408152 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of ART services
Number of subjects: 21
Study 28451891 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Behavior Therapy (ABBT)
Number of subjects: 34
Study 28451891 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 34
Study 26112656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol 5/5 µg
Number of subjects: 5162
Study 26112656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol 2.5/5 µg
Number of subjects: 5162
Study 26112656 — intervention group
Group type: COMPARATOR
Intervention: Olodaterol 5 µg
Number of subjects: 5162
Study 26112656 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 5 µg
Number of subjects: 5162
Study 22930151 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF‐A assay
Number of subjects: 60
Study 22930151 — intervention group
Group type: EXPERIMENTAL
Intervention: CA‐125 assay
Number of subjects: 60
Study 22930151 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF‐A level post-operation
Number of subjects: 60
Study 22930151 — intervention group
Group type: EXPERIMENTAL
Intervention: CA‐125 level post-operation
Number of subjects: 60
Study 22930151 — intervention group
Group type: COMPARATOR
Intervention: Comparison of VEGF‐A and CA-125
Number of subjects: 60
Study 22019148 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrate (BMAC)
Number of subjects: 48
Study 22019148 — intervention group
Group type: COMPARATOR
Intervention: Sham injections (dilute blood)
Number of subjects: 48
Study 18631346 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with grass pollen extract
Number of subjects: 204
Study 18631346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 16461190 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP increase (10 mm Hg)
Number of subjects: 53163
Study 16461190 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP increase (10 mm Hg)
Number of subjects: 53163
Study 16461190 — intervention group
Group type: COMPARATOR
Intervention: Systolic BP compared to pulse pressure and mean arterial pressure
Number of subjects: 53163
Study 12006900 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine maintenance treatment
Number of subjects: 51
Study 12006900 — intervention group
Group type: COMPARATOR
Intervention: Placebo substitution
Number of subjects: 51
Study 10211147 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (n = 513)
Number of subjects: 1714
Study 10211147 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (n = 114)
Number of subjects: 1714
Study 10211147 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (n = 522)
Number of subjects: 1714
Study 8529326 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg oral dose
Number of subjects: 0
Study 8529326 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyitraconazole (derived from itraconazole)
Number of subjects: 0
Study 8529326 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin 300 mg oral dose
Number of subjects: 0
Study 2221962 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI cranial scans (Group A)
Number of subjects: 115
Study 2221962 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI spinal scans (Group B)
Number of subjects: 115
Study 2221962 — intervention group
Group type: COMPARATOR
Intervention: CTM (Group B)
Number of subjects: 115
Study 274992 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG administered by the multiple-puncture technique
Number of subjects: 12
Study 274992 — intervention group
Group type: COMPARATOR
Intervention: Control (no BCG)
Number of subjects: 12
Study 31792893 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical object looked at earlier and for longer when semantically unrelated to other objects in the display during target-present trials.
Number of subjects: 0
Study 31792893 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical object looked at earlier and for longer when semantically unrelated to other objects in the display during target-absent trials.
Number of subjects: 0
Study 28569525 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management intervention (VetChange) for problem drinking
Number of subjects: 523
Study 27590668 — intervention group
Group type: EXPERIMENTAL
Intervention: iPeer2Peer Program (intervention group)
Number of subjects: 30
Study 27590668 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 30
Study 25017001 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (N=115)
Number of subjects: 241
Study 25017001 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (N=126)
Number of subjects: 241
Study 22494068 — intervention group
Group type: EXPERIMENTAL
Intervention: Gracey curettes with 15 vertical strokes
Number of subjects: 20
Study 22494068 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoceramic ultrasonic scaler with a power of 11
Number of subjects: 20
Study 22494068 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery ultrasonic scaler in mode ROOT with a power of two
Number of subjects: 20
Study 22494068 — intervention group
Group type: COMPARATOR
Intervention: Termination diamond burs (40 μm) at 3000 r.p.m.
Number of subjects: 20
Study 20018807 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus tea (3 240‐mL servings/d for 6 weeks)
Number of subjects: 65
Study 20018807 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 65
Study 17767927 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of fillings (Group A)
Number of subjects: 82
Study 17767927 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal and non-specific detoxification (Group B)
Number of subjects: 82
Study 17767927 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups A+B
Number of subjects: 82
Study 17767927 — intervention group
Group type: COMPARATOR
Intervention: Health promotion program without removal (Group C)
Number of subjects: 82
Study 16556720 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/day (n = 16)
Number of subjects: 30
Study 16556720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 30
Study 12903044 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA‐DRB1 low resolution typing
Number of subjects: 2810
Study 12903044 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA‐DRB1 high resolution typing by polymerase chain reaction‐sequence specific primers technique
Number of subjects: 2810
Study 10668524 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 0
Study 8912488 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsive treatment with carbamazepine
Number of subjects: 91
Study 8912488 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 91
Study 1672512 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 14
Study 1672512 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 14
Study 1672512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 7257029 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin therapy
Number of subjects: 59